HTGC : Summary for Hercules Capital, Inc. Common S - Yahoo Finance

U.S. Markets closed

Hercules Capital, Inc. (HTGC)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
13.67-0.07 (-0.51%)
At close: 4:02 PM EST
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close13.74
Bid13.41 x 200
Ask13.84 x 100
Day's Range13.56 - 13.73
52 Week Range9.92 - 14.00
Avg. Volume312,729
Market Cap1.06B
PE Ratio (TTM)14.70
Earnings DateN/A
Dividend & Yield1.24 (9.10%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Is It Time to Sell The Ensign Group, Inc. (ENSG)?
    Insider Monkeyyesterday

    Is It Time to Sell The Ensign Group, Inc. (ENSG)?

    Hedge fund managers like David Einhorn, Dan Loeb, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer’s Elliott Management, are pretty secretive, but we can still get some insights by analyzing […]

  • Barrons.com5 days ago

    8 BDCs Most Likely to Benefit from Higher Rates

    Trump administration policies -- like lower taxes, increased infrastructure spending and less regulation on banks -- are likely to lead to more inflation and are already sparking higher interest rates. ...

  • PR Newswire12 days ago

    Sorrento Therapeutics, Inc. Secures $75 Million Loan Facility

    SAN DIEGO, Nov. 28, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (SRNE) ("Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announces it has entered into a loan and security agreement with Hercules Capital, Inc. (HTGC) ("Hercules") for a term loan of up to $75.0 million subject to funding in three tranches. The proceeds will be used for general corporate purposes allowing Sorrento the flexibility to consolidate core programs and more rapidly advance product opportunities in various therapeutic areas. A first tranche of $50.0 million was funded upon execution of the loan agreement on November 23, 2016.